Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02719132
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 24
- Registration Number
- NCT02700334
- Locations
- 🇲🇽
Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 120
- Registration Number
- NCT02695810
- Locations
- 🇩🇰
Steno Diabetes Center A/S, Gentofte, Denmark
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 905
- Registration Number
- NCT02681094
- Locations
- 🇷🇺
Research Site, Vladikavkaz, Russian Federation
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Saint Luke's Health System
- Target Recruit Count
- 263
- Registration Number
- NCT02653482
- Locations
- 🇺🇸
University of Southern Califiornia, Los Angeles, California, United States
🇺🇸Heart Group of the Eastern Shore, Fairhope, Alabama, United States
🇺🇸NorthShore University HealthSystem Research Institute, Evanston, Illinois, United States
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 632
- Registration Number
- NCT02616666
- Locations
- 🇬🇧
Research Site, Wembley, United Kingdom
🇬🇧Research Site, Alum Rock, Birmingham, United Kingdom
🇬🇧Research Site, Market Square, Kineton, United Kingdom
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-08-14
- Target Recruit Count
- 56
- Registration Number
- NCT02613897
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT02610088
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Effect of Dapagliflozin on Inflammation and Endothelial Function
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT02608905
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2020-09-17
- Target Recruit Count
- 30
- Registration Number
- NCT02592421
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.